These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 29925684)

  • 1. Intranasal carbetocin reduces hyperphagia in individuals with Prader-Willi syndrome.
    Dykens EM; Miller J; Angulo M; Roof E; Reidy M; Hatoum HT; Willey R; Bolton G; Korner P
    JCI Insight; 2018 Jun; 3(12):. PubMed ID: 29925684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal Carbetocin Reduces Hyperphagia, Anxiousness, and Distress in Prader-Willi Syndrome: CARE-PWS Phase 3 Trial.
    Roof E; Deal CL; McCandless SE; Cowan RL; Miller JL; Hamilton JK; Roeder ER; McCormack SE; Roshan Lal TR; Abdul-Latif HD; Haqq AM; Obrynba KS; Torchen LC; Vidmar AP; Viskochil DH; Chanoine JP; Lam CKL; Pierce MJ; Williams LL; Bird LM; Butler MG; Jensen DE; Myers SE; Oatman OJ; Baskaran C; Chalmers LJ; Fu C; Alos N; McLean SD; Shah A; Whitman BY; Blumenstein BA; Leonard SF; Ernest JP; Cormier JW; Cotter SP; Ryman DC
    J Clin Endocrinol Metab; 2023 Jun; 108(7):1696-1708. PubMed ID: 36633570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxytocin in young children with Prader-Willi syndrome: Results of a randomized, double-blind, placebo-controlled, crossover trial investigating 3 months of oxytocin.
    Damen L; Grootjen LN; Juriaans AF; Donze SH; Huisman TM; Visser JA; Delhanty PJD; Hokken-Koelega ACS
    Clin Endocrinol (Oxf); 2021 May; 94(5):774-785. PubMed ID: 33296519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal oxytocin versus placebo for hyperphagia and repetitive behaviors in children with Prader-Willi Syndrome: A randomized controlled pilot trial.
    Hollander E; Levine KG; Ferretti CJ; Freeman K; Doernberg E; Desilva N; Taylor BP
    J Psychiatr Res; 2021 May; 137():643-651. PubMed ID: 33190843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The behavioral impact of growth hormone treatment for children and adolescents with Prader-Willi syndrome: a 2-year, controlled study.
    Whitman BY; Myers S; Carrel A; Allen D
    Pediatrics; 2002 Feb; 109(2):E35. PubMed ID: 11826245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Behavioral changes in patients with Prader-Willi syndrome receiving diazoxide choline extended-release tablets compared to the PATH for PWS natural history study.
    Strong TV; Miller JL; McCandless SE; Gevers E; Yanovski JA; Matesevac L; Bohonowych J; Ballal S; Yen K; Hirano P; Cowen NM; Bhatnagar A
    J Neurodev Disord; 2024 Apr; 16(1):22. PubMed ID: 38671361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcranial direct current stimulation reduces food-craving and measures of hyperphagia behavior in participants with Prader-Willi syndrome.
    Bravo GL; Poje AB; Perissinotti I; Marcondes BF; Villamar MF; Manzardo AM; Luque L; LePage JF; Stafford D; Fregni F; Butler MG
    Am J Med Genet B Neuropsychiatr Genet; 2016 Mar; 171B(2):266-75. PubMed ID: 26590516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxytocin treatment in children with Prader-Willi syndrome: A double-blind, placebo-controlled, crossover study.
    Miller JL; Tamura R; Butler MG; Kimonis V; Sulsona C; Gold JA; Driscoll DJ
    Am J Med Genet A; 2017 May; 173(5):1243-1250. PubMed ID: 28371242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trial.
    Allas S; Caixàs A; Poitou C; Coupaye M; Thuilleaux D; Lorenzini F; Diene G; Crinò A; Illouz F; Grugni G; Potvin D; Bocchini S; Delale T; Abribat T; Tauber M
    PLoS One; 2018; 13(1):e0190849. PubMed ID: 29320575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promising effects of oxytocin on social and food-related behaviour in young children with Prader-Willi syndrome: a randomized, double-blind, controlled crossover trial.
    Kuppens RJ; Donze SH; Hokken-Koelega AC
    Clin Endocrinol (Oxf); 2016 Dec; 85(6):979-987. PubMed ID: 27486141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of topiramate on eating behaviours in Prader-Willi syndrome: TOPRADER double-blind randomised placebo-controlled study.
    Consoli A; Çabal Berthoumieu S; Raffin M; Thuilleaux D; Poitou C; Coupaye M; Pinto G; Lebbah S; Zahr N; Tauber M; Cohen D; Bonnot O
    Transl Psychiatry; 2019 Nov; 9(1):274. PubMed ID: 31685813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized pilot efficacy and safety trial of diazoxide choline controlled-release in patients with Prader-Willi syndrome.
    Kimonis V; Surampalli A; Wencel M; Gold JA; Cowen NM
    PLoS One; 2019; 14(9):e0221615. PubMed ID: 31545799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A disease specific questionnaire for assessing behavior in individuals with Prader-Willi syndrome.
    Avrahamy H; Pollak Y; Shriki-Tal L; Genstil L; Hirsch HJ; Gross-Tsur V; Benarroch F
    Compr Psychiatry; 2015 Apr; 58():189-97. PubMed ID: 25677112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind randomized controlled trial of oxytocin nasal spray in Prader Willi syndrome.
    Einfeld SL; Smith E; McGregor IS; Steinbeck K; Taffe J; Rice LJ; Horstead SK; Rogers N; Hodge MA; Guastella AJ
    Am J Med Genet A; 2014 Sep; 164A(9):2232-9. PubMed ID: 24980612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Caregiver priorities for endpoints to evaluate treatments for Prader-Willi syndrome: a best-worst scaling.
    Tsai JH; Scheimann AO; McCandless SE; Strong TV; Bridges JFP
    J Med Econ; 2018 Dec; 21(12):1230-1237. PubMed ID: 30256699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and emerging therapies for managing hyperphagia and obesity in Prader-Willi syndrome: A narrative review.
    Tan Q; Orsso CE; Deehan EC; Triador L; Field CJ; Tun HM; Han JC; Müller TD; Haqq AM
    Obes Rev; 2020 May; 21(5):e12992. PubMed ID: 31889409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: A randomized, double-blind, placebo-controlled trial.
    McCandless SE; Yanovski JA; Miller J; Fu C; Bird LM; Salehi P; Chan CL; Stafford D; Abuzzahab MJ; Viskochil D; Barlow SE; Angulo M; Myers SE; Whitman BY; Styne D; Roof E; Dykens EM; Scheimann AO; Malloy J; Zhuang D; Taylor K; Hughes TE; Kim DD; Butler MG
    Diabetes Obes Metab; 2017 Dec; 19(12):1751-1761. PubMed ID: 28556449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diazoxide Choline Extended-Release Tablet in People With Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled Trial.
    Miller JL; Gevers E; Bridges N; Yanovski JA; Salehi P; Obrynba KS; Felner EI; Bird LM; Shoemaker AH; Angulo M; Butler MG; Stevenson D; Abuzzahab J; Barrett T; Lah M; Littlejohn E; Mathew V; Cowen NM; Bhatnagar A;
    J Clin Endocrinol Metab; 2023 Jun; 108(7):1676-1685. PubMed ID: 36639249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptides associated with hyperphagia in adults with Prader-Willi syndrome before and during GH treatment.
    Höybye C; Barkeling B; Espelund U; Petersson M; Thorén M
    Growth Horm IGF Res; 2003 Dec; 13(6):322-7. PubMed ID: 14624765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of hyperphagia in Prader-Willi syndrome.
    Dykens EM; Maxwell MA; Pantino E; Kossler R; Roof E
    Obesity (Silver Spring); 2007 Jul; 15(7):1816-26. PubMed ID: 17636101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.